A Phase 3 interventional study of Tranexamic Acid and placebo in Femoral Neck Fracture, sponsored by Dr. Jeff Yach. Terminated at 1 site in Canada. Open to participants aged 65 Years to 95 Years. Per ClinicalTrials.gov, last updated 2018-11-30.
Sponsored by Dr. Jeff Yach · Phase 3, Interventional, and Treatment
Tranexamic acid (TA) is a synthetic antifibrinolytic agent. It prevents degradation of fibrin and delays the breakdown of hemostatic clots. It has been demonstrated in multiple studies and meta analyses to decrease blood loss in elective hip and knee arthroplasty. However, concerns about the prothrombotic side effects of systemic administration of TA has hindered the widespread adoption of this medication in orthopaedic patients due to their high risk for thrombotic complications such as deep venous thrombosis and pulmonary embolism Topical application of tranexamic acid has been proposed as a way to mitigate the potential prothrombotic effects of TA. Topical application of TA has been demonstrated to be beneficial in oral and cardiac surgery. Plasma levels of TA have been found to be minimal following topical application, minimizing its potential systemic thromboembolic side effects. TA has been used topically in total knee arthroplasty, with significant reductions in blood loss and no increase in thromboembolic complications8,10. Data on the use of TA in hip fracture surgery is limited, and there are no studies examining topical use of TA in hip fracture surgery.
Our study question is: Does topical tranexamic acid decrease blood loss following hemiarthroplasty of the hip for femoral neck fractures? The type of information collected by the research assistant will consist of estimated blood loss during surgery, length of stay in hospital, any wound infections as well as any thromboembolic side effects (blood clots in legs and/or heart) that may occur. The number of units of red blood cells transfused will be recorded up to and including postoperative day 8. Preoperative hemoglobin and lowest postoperative hemoglobin levels up to and including post-op day 8 will also be collected as well as any use of ambulatory aids will be recorded on presentation to hospital, discharge and 6 weeks post operatively.
144 studies on the registry are indexed under Postoperative Hemorrhage; 28 are open to participants now.
This study's enrollment of 15 is below the median of 100 across 103 interventional studies indexed under Postoperative Hemorrhage.
Browse Postoperative Hemorrhage studies →This is the only study on the registry with Dr. Jeff Yach as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
3000mg/mL tranexamic acid in saline applied directly to the wound at the end of the surgical procedure.
Drug: Tranexamic Acid
3000mg/mL saline applied directly to the wound at the end of the surgical procedure
Other: placebo
drug and placebo applied topically at end of surgery at hip site.
Also known as: Cyklokapron
applied topically to surgical site in OR.
Also known as: saline solution
Blood loss
Time frame: postop 0-8 days.
This study is terminated, as verified in Nov 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.